Treatment of Preeclampsia with TTR (Case 1997)

Principal Investigators:


Surendra Sharma, PhD, Professor

Department of Bio Med Pathology & Laboratory Medicine
Brown University

Providence, RI

Brief Description:


Preeclampsia (PE) and other hypertensive disorders of pregnancy are a leading cause of maternal and infant illness and death, worldwide, with 7-8% of all pregnancies affected. PE is a multi-symptomatic, systemic, and rapidly progressive condition, involving elevated blood pressure, general edema and proteinuria, with many other potential symptoms; it affects the mother and unborn baby. Some patients with advancing disease experience symptoms that affect other vascular organs like brain and liver. PE is believed to be a placental condition that resolves after delivery or pregnancy termination leading to preterm birth.


Efforts have been made to provide diagnostic assays for PE; these assays attempt to identify and measure a variety of biomarkers (proteins, nucleic acids) in maternal samples. Proteomics based studies suggest transthyretin (TTR) - previously known as prealbumin – as a potential biomarker. Current treatment of PE is primarily through close monitoring of maternal and fetal health/symptoms either by hospitalization or outpatient setting. Induction or pregnancy termination is the treatment, if the condition worsens to life threatening in either the mother or unborn baby, regardless of gestational age. Therapeutic intervention in PE and PE-type disorders would significantly improve treatment and outcomes.


The invention is a novel method and use of a TTR therapeutic in the treatment of PE-type disorders, to alleviate symptoms and control progression of, and potentially act as a prophylactic against PE. Therapeutic administration may be through multiple routes (oral, intravenous, etc.), and individual or in an admixture with conventional pharmaceutical vehicle/carrier(s).


Application is in the treatment of human preeclampsia and PE-type disorders, during pregnancy and/or post-partum. The pharmaceutical market is indicated with a market segment of obstetrics and gynecology (OB-GYN) including prenatal healthcare. Also, this invention may have future implications for use in treating Alzheimer’s and amyotrophic lateral sclerosis (ALS).




US patent application 14/676,132 is pending

Corresponding foreign application is pending

Patent Information:
For Information, Contact:
Margaret Shabashevich,
Manager of Operations
Technology Ventures Office
Brown University
Surendra Sharma
Satyan Kalkunte
Udo Markert
© 2017. All Rights Reserved. Powered by Inteum